Collegium Pharmaceutical, Inc. - stock earnings
COLL Upcoming estimated earnings
| Date | Actual / Estimated EPS | Low Revenue | Actual / Estimated Revenue | High Revenue |
|---|---|---|---|---|
| May 2, 2024 AfterMarket | - / 1.5000000000 | - | - / 147.5 million | - |
COLL Quarterly earnings
| Date | Earnings | Revenue |
|---|---|---|
| 2023Q4 | 31.9 million USD | 149.7 million USD |
| 2023Q3 | 20.6 million USD | 136.7 million USD |
| 2023Q2 | 13.0 million USD | 135.5 million USD |
| 2023Q1 | -17.4 million USD | 144.8 million USD |
| 2022Q4 | -7.2 million USD | 129.6 million USD |
| 2022Q3 | 457000 USD | 127.0 million USD |
| 2022Q2 | -5.2 million USD | 123.5 million USD |
| 2022Q1 | -13.1 million USD | 83.8 million USD |
| 2021Q4 | -25.0 million USD | 27.4 million USD |
| 2021Q3 | 8.0 million USD | 78.8 million USD |
| 2021Q2 | 72.8 million USD | 82.9 million USD |
| 2021Q1 | 15.7 million USD | 87.7 million USD |
| 2020Q4 | 7.0 million USD | 76.3 million USD |
| 2020Q3 | 11.3 million USD | 79.2 million USD |
| 2020Q2 | 8.1 million USD | 78.1 million USD |
| 2020Q1 | 450000 USD | 76.5 million USD |
| 2019Q4 | -2.2 million USD | 74.2 million USD |
| 2019Q3 | -6.1 million USD | 72.9 million USD |
| 2019Q2 | -4.7 million USD | 75.0 million USD |
| 2019Q1 | -9.7 million USD | 74.5 million USD |
| 2018Q4 | 9.1 million USD | 73.4 million USD |
| 2018Q3 | -16.5 million USD | 70.2 million USD |
| 2018Q2 | -13.1 million USD | 73.1 million USD |
| 2018Q1 | -18.7 million USD | 63.7 million USD |
| 2017Q4 | -17.4 million USD | 10.8 million USD |
| 2017Q3 | -13.3 million USD | 12.0 million USD |
| 2017Q2 | -21.1 million USD | 3.6 million USD |
| 2017Q1 | -23.1 million USD | 2.2 million USD |
| 2016Q4 | -27.6 million USD | 1.3 million USD |
| 2016Q3 | -26.4 million USD | 408000 USD |
| 2016Q2 | -24.5 million USD | ? USD |
| 2016Q1 | -15.7 million USD | ? USD |
| 2015Q4 | -9.5 million USD | ? USD |
| 2015Q3 | -9.4 million USD | ? USD |
| 2015Q2 | -4.7 million USD | ? USD |
| 2015Q1 | -3.7 million USD | ? USD |
| 2014Q4 | -3.5 million USD | ? USD |
| 2014Q3 | -6.6 million USD | ? USD |
| 2014Q2 | -4.1 million USD | ? USD |
| 2014Q1 | -3.8 million USD | ? USD |
COLL Yearly earnings
| Date | Earnings | Revenue |
|---|---|---|
| 2023 | 48.2 million USD | 566.8 million USD |
| 2022 | -25.0 million USD | 463.9 million USD |
| 2021 | 71.5 million USD | 276.9 million USD |
| 2020 | 26.8 million USD | 310.0 million USD |
| 2019 | -8.1 million USD | 296.7 million USD |
| 2018 | -39.1 million USD | 280.4 million USD |
| 2017 | -74.9 million USD | 28.5 million USD |
| 2016 | -94.2 million USD | 1.7 million USD |
| 2015 | -27.3 million USD | ? USD |
| 2014 | -17.9 million USD | ? USD |
| 2013 | -16.2 million USD | ? USD |
COLL
Price: $37.51
52 week price:
Earnings Per Share: 1.29 USD
P/E Ratio: 141.71
Exchange: NMS
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Volume: 465500
Ebitda: -13.3 millionMarket Capitalization: 1.2 billion